High Quality Posaconazole CAS 171228-49-2 Noxafil for Antifungal

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: Frazer-Posaconazole
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Adult
• State: White Powder
• Purity: >99%
• CAS No.: 171228-49-2
• Colour: White
• Appearance: White Powder
• Shelf Life: 2 Years
• Storage: Store in a Well-Closed Container Away From Moistur
• Form: Powder
• Delivery: Express 5-7 Days Arrive
• Storage Temp.: -20°c Freezer
• Melting Point: 170-172°c
• Grade: Pharmaceutical Grade
• Usage: Orally Active Triazole Antifungal
• Transport Package: Foil Bag
• Specification: 1kg Per Foil Bag, 10 Bags Per Carton, 25 Kg Per Dr
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 800kg/Month

Product Description

High Quality Posaconazole CAS 171228-49-2 Noxafil for Antifungal
 

 

Specification of Analysis

Items	Standards		Results
Characteristics	White to off-white powder		White powder
Identification	By IR		Complies
	By HPLC		Complies
Specific Rotation	-28°~-34°		-32°
Water Content	≤ 2.00%		0.20%
Heavy Metals	≤ 10ppm		Complies
Sulfated Ash	≤ 0.10%		0.03%
Related Substances	Any single impurity: ≤0.10%		0.03%
	Total Impurities: ≤0.50%		0.09%
Assay (HPLC basis on drying)	98.0%~102.0%		99.98%
Reference Standard	In-house Standard
Conclusion	The product complied to In-house standard.
Storage	Preserve in tight,light-resistant containers in a cool

Description:

Posaconazole, launched in the UK, is the newest member of the class of antifungal agents to reach the market. It is indicated for the treatment and prophylaxis of a range of invasive fungal infections, including aspergillosis,fusariosis, chromoblastomycosis, mycetoma, and coccidiomycosis in patients who are refractory to, or intolerant of, standard therapy with amphotericin B and/or itraconazole. In the US, it is approved for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age who are at high risk of developing these infections due to being severely immunocompromised. Additionally, it is approved for the treatment of oropharyngeal candidiasis. Posaconazole has an expanded spectrum of activity over other members of the antifungals. In addition to potent activity against refractory cases of aspergillosis and fluconazole-resistant Candida, it demonstrates activity against Zygomycetes.

Function and Application:

Posaconazole is used for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as HSCT recipients with GVHD or those with hematologic malignancies with prolonged neutropenia from chemotherapy. 
Posaconazole is also used for the treatment of oropharyngeal candidiasis (OPC), including OPC refractory to itraconazole and/or fluconazole therapy. 
Posaconazole is also used to treat invasive infections by Candida, Mucor, and Aspergillus species in severely immunocompromised patients.